Affimed ASCO Data Demonstrate Consistent Potency of NK- Cell-Engaging Combination Therapy with Checkpoint Modulators

Press Release - May 29, 2015

Affimed’s lead NK-cell engager AFM13 shows highly synergistic efficacy with PD-1 inhibitor

Heidelberg, Germany, May 29, 2015 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today provided details on preclinical data from a combination study of Affimed’s lead candidate AFM13 with checkpoint modulators, including checkpoint inhibitor PD-1. These data will be presented on Saturday, May 30, at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting being held May 29 – June 2, 2015 in Chicago, IL.

The poster titled “CD137 co-stimulation and blocking PD-1 enhances NK-cell-mediated target lysis by CD30/CD16A TandAb AFM13” (Abstract #3050) outlines the results of four preclinical studies developed by Dr. Holbrook Kohrt at Stanford University in Patient-Derived Tumor Graft (PDX) mice to analyze Affimed’s AFM13 in combination with checkpoint modulating agents. In this model, which develops actual human tumors, AFM13, a first-in-class natural killer (NK-) cell engager, demonstrated significant synergy in combination with a PD-1 inhibitor. Importantly, these preclinical results were consistent among the four individual studies.

Specifically, tumor samples were surgically obtained from four newly diagnosed CD30+ Hodgkin lymphoma patients. These tumors were xenografted into mice and allowed to grow for 28 days before the mice were infused with the respective patient’s peripheral blood mononuclear cells (PBMCs) and treated on a weekly basis with either monotherapy (IgG control, AFM13, anti-CTLA-4, anti-PD-1, or anti-CD137) or a combination regimen (AFM13 plus anti-CTLA-4, anti-PD-1, or anti-CD137). The mice received three weekly treatments via intraperitoneal injection and tumor size was compared between groups on day 58. The mean results for all patients demonstrated:

  • Of all single agents investigated, AFM13 showed the most potent anti-tumor efficacy.
  • As single agents, AFM13 and anti-PD-1 were able to demonstrate tumor shrinkage.
  • Treatment with the combination of AFM13 with an anti-PD-1 resulted in an impressive decrease in tumor volume, in some cases with complete tumor eradication.
  • As a single agent, AFM13 led to substantial tumor-infiltration of NK-cells, which was enhanced by the combination with anti-CTLA-4, anti-CD137, and anti-PD-1.
  • Increased number of tumor-infiltrating cytotoxic T-cells, especially with the combination of AFM13 with anti-PD-1 and anti-CTLA-4.

“These striking preclinical results, in particular the combination of AFM13 with a PD-1 inhibitor, along with AFM13’s good clinical safety profile in patients, strongly advocate for the further investigation of the combination therapy in hematologic malignancies expressing CD30,” stated Dr. Holbrook Kohrt.

Natural killer cells or NK-cells are one of the key drivers of innate immunity. The innate immune system is the body’s first line of response to aberrant cells such as cancer cells. Hence, every cancer cell that survives in the human body must initially develop protection mechanisms in order to avoid its destruction by the innate immune cells. Affimed’s approach to redirect NK-cells to the tumor through its CD16A bispecific TandAb-platform is aiming to reestablish the killing mechanism by the innate immune system. As the innate immune system is also the gate keeper of the adaptive immune system, namely the T- and B-cells, this redirection and killing of cancer cells may also be crucial to activating the adaptive immune response. Affimed is presently investigating this clinically with AFM13 as a monotherapy and is planning to initiate a clinical study with AFM 13 in combination with a checkpoint inhibitor. AFM13 is the only CD16A NK-cell engager currently in clinical investigations in the world.

About AFM13
AFM13 is a first-in-class bispecific NK-cell TandAb®, which binds NK-cells specifically via CD16A and has a second binding domain for CD30, a cancer-specific target. CD16A is expressed on NK-cells, highly potent cytotoxic effector cells of the innate immune system, enabling AFM13 to selectively bind these effector cells. AFM13 redirects the NK-cells to CD30-expressing cancer cells and binds both targets with high affinity, establishing a bridge whereby the NK-cells are activated and redirected to kill the cancer cells. AFM13 is designed to treat CD30-positive malignancies including Hodgkin lymphoma (HL) and T-cell lymphoma (TCL) and is currently in phase 2 studies in HL patients. Like all TandAbs®, AFM13 is a stable, off-the-shelf, targeted immunotherapeutic which does not require continuous infusion due to a favorable half-life in a patient’s bloodstream, yet is tunable by dosing adjustment when required. This highly specific NK-cell antibody and the related bispecific platform are unique to Affimed.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed’s proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit

Affimed Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates our intellectual property position, our collaboration activities, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in Affimed’s filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Affimed IR Contact

Caroline Stewart, Head IR & Communication
Phone: +1 347 394 6793
E-Mail: email hidden; JavaScript is required or email hidden; JavaScript is required

Media Requests

Anca Alexandru or Gretchen Schweitzer
MacDougall Biomedical Communications
Phone: +49 89 2424 3494 or +49 163 613 3359
E-Mail: email hidden; JavaScript is required